August 2017

New Product - Pedea

Pedea (ibuprofen) is indicated for the treatment of haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. Pedea should not be administered in life threatening infection; active bleeding, especially intracranial or gastrointestinal haemorrhage; thrombocytopenia or coagulation defects; significant impairment of renal function; congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow (e.g. pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta); known or suspected necrotising enterocolitis. Pedea 5 mg/mL solution for intravenous infusion is available in 2 mL ampoules in packs of 4.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au